Bio-Rad Laboratories, Inc.
BIO
$265.26
$0.940.36%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 124.08% | -571.34% | -189.38% | -388.83% | -209.46% |
| Total Depreciation and Amortization | 5.95% | 3.53% | 3.91% | 3.74% | 4.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -103.11% | 267.19% | 113.12% | 118.26% | 111.45% |
| Change in Net Operating Assets | 119.71% | -86.47% | -43.44% | -48.78% | -42.17% |
| Cash from Operations | 54.33% | 48.67% | 21.41% | 10.29% | 20.67% |
| Capital Expenditure | 3.31% | 0.83% | -5.71% | -10.56% | -27.20% |
| Sale of Property, Plant, and Equipment | -58.62% | -46.00% | -46.00% | 67.55% | 183.70% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.05% | -77.89% | -96.93% | 171.92% | 252.31% |
| Cash from Investing | -1,656.52% | -340.01% | -892.97% | 48.03% | 94.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 18.45% | 37.78% | 7.20% | -16.67% | -16.84% |
| Issuance of Common Stock | -8.69% | -7.99% | 3.85% | 6.07% | 2.91% |
| Repurchase of Common Stock | -0.44% | 32.14% | 53.34% | -24.88% | -9.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -4,897.17% | -4,897.17% | -- | -1,150.00% | -1,150.00% |
| Cash from Financing | -10.03% | 26.37% | 48.58% | -26.16% | -10.19% |
| Foreign Exchange rate Adjustments | -345.49% | -7.65% | 2,201.50% | 33.55% | 162.21% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 20.93% | -100.00% |
| Net Change in Cash | -308.80% | 391.12% | 383.57% | 23.08% | 108.36% |